S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Foundation Medicine’s Novel Companion Diagnostic Test, Developed in Collaboration with Clovis Oncology, Identifies Expanded Subgroup of Cancer Patients with the Potential to Respond to Clovis Oncology’s PARP inhibitor, Rucaparib|
|Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer|
|Clovis Oncology Enters into Oncology Clinical Trial Collaboration with GlaxoSmithKline|
|Interim Data from Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling and Durable Clinical Activity and Progression-free Survival (PFS) in Patients with EGFR-Mutant Non-small Cell Lung Cancer (NSCLC)|
|Clovis Oncology Announces Third Quarter 2014 Operating Results|
|Clovis Oncology Announces First Patient Enrolled in TIGER-1 Study|
|Initial Data from Ongoing Phase 2 ARIEL2 Study of Rucaparib in Ovarian Cancer Demonstrate Encouraging Clinical Activity and Safety in both BRCA Mutant and BRCAness Patients|
|Clovis Oncology to Present at the 2014 Credit Suisse Healthcare Conference|
|Clovis Oncology to Present at the 33rd Annual J.P. Morgan Healthcare Conference|
|Nektar Presents Preclinical Study Findings for Etirinotecan Pegol (NKTR-102) in Combination with a PARP Inhibitor in BRCA1-deficient Cancer Model|
Click above to view more mutual fund data and stats for clvs - Clovis Oncology Inc.